NanoVibronix corrects Series G Preferred Stock floor price in charter filing

Published 09/07/2025, 21:36
NanoVibronix corrects Series G Preferred Stock floor price in charter filing

NanoVibronix , Inc. (NASDAQ:NAOV), a micro-cap company with a market value of $2.45 million and currently trading at $0.95 per share, filed a certificate of correction with the Delaware Secretary of State on Tuesday to amend a typographical error in its Series G Preferred Stock designation, according to a press release statement based on a recent SEC filing.

The correction addresses the definition of the “Floor Price” in Section 1 of the company’s Certificate of Designation of the Preferences, Rights and Limitations of Series G Preferred Stock. The original document stated the floor price as $1.02, which was an error. The corrected floor price is $1.91.

No other provisions of the Certificate of Designation were changed as a result of this filing.

The certificate of correction was filed on July 8, 2025. NanoVibronix’s common stock is listed on the Nasdaq Capital Market under the ticker NAOV.

This information is based on a press release statement contained in the company’s Form 8-K filed with the Securities and Exchange Commission.

In other recent news, NanoVibronix, Inc. announced the pricing of a public offering expected to raise approximately $10 million before fees and expenses, with the closing anticipated around May 19, 2025. The funds will be used to redeem a principal amount of outstanding debentures and partially repay an outstanding note, as well as for general corporate purposes. Additionally, the company has regained full compliance with Nasdaq Capital Market’s continued listing requirements, closing a previous listing matter and ensuring continued trading under Nasdaq rules. In another development, NanoVibronix has been granted a U.S. patent for its pediatric feeding tube guidance system, a technology aimed at improving tube placement in pediatric patients. The company is preparing to seek FDA 510(k) clearance for pediatric use of this system. Following the acquisition of ENvue Medical (TASE:BLWV) Holdings, NanoVibronix appointed Doron Besser as the new CEO, replacing Brian Murphy, who retired but remains on the Board of Directors. The transition aims to enhance the company’s product portfolio and drive growth. Furthermore, NanoVibronix refuted false claims about a $26 million stock offering, emphasizing that no such offering is being executed and that the company is investigating the source of the misinformation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.